Clinical Trials Directory

Trials / Sponsors / Shanghai Kechow Pharma, Inc.

Shanghai Kechow Pharma, Inc.

Industry · 12 registered clinical trials — 4 currently recruiting.

StatusTrialPhaseStarted
RecruitingSafety, Tolerability, and Pharmacokinetics of HL-003 in Healthy Subjects
Healthy Subjects
Phase 12025-02-28
RecruitingComparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Melanoma
Phase 32023-11-02
RecruitingEfficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal
Colorectal Cancer Metastatic
Phase 32023-10-25
UnknownEfficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer
Non-small-cell Lung Cancer
Phase 22023-09-24
UnknownStudy of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)
CRC
Phase 22022-02-24
RecruitingHL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Neurofibromatosis 1, Plexiform Neurofibromas
Phase 22021-10-18
UnknownHL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
Melanoma
Phase 22021-09-06
CompletedHL-085 in NRAS-mutated Advanced Melanoma
Melanoma
Phase 22020-11-02
TerminatedStudy of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC
Nsclc
Phase 12020-05-21
TerminatedPhase I Study of HL-085 in Patients With Advanced Solid Tumors
Solid Tumor, Adult
Phase 12019-06-17
UnknownA PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation
Solid Tumor
Phase 12018-07-01
CompletedStudy of HL-085 in NRAS Mutant Advanced Melanoma
Melanoma
Phase 1 / Phase 22017-09-01